Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease: Lights and Shadows

Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease: Lights and Shadows

Rheumatoid arthritis (RA) is a chronic and systemic inflammatory disease affecting 0.5–1% of the population worldwide. Interstitial lung disease (ILD) is a serious pulmonary complication of RA and it is responsible for 10–20% of mortality, with a mean survival of 5–8 years. However, nowadays there a...

Full description

Bibliographic Details
Main Authors: Giulia Cassone, Andreina Manfredi, Caterina Vacchi, Fabrizio Luppi, Francesca Coppi, Carlo Salvarani, Marco Sebastiani
Format: Article
Language:English
Published: MDPI AG 2020-04-01
Series:Journal of Clinical Medicine
Subjects:
rheumatoid arthritis
interstitial lung disease
therapy
DMARDs
antifibrotic agents
Online Access:https://www.mdpi.com/2077-0383/9/4/1082

Internet

https://www.mdpi.com/2077-0383/9/4/1082

Similar Items